Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-30,000
Closed -$3.29M 5121
2023
Q4
$3.29M Buy
+30,000
New +$3.1M ﹤0.01% 2484
2023
Q1
Sell
-170,000
Closed -$15.1M 5127
2022
Q4
$15.1M Hold
170,000
0.01% 1017
2022
Q3
$13.6M Buy
+170,000
New +$16M 0.01% 741
2022
Q1
Sell
-107,400
Closed -$15.2M 5030
2021
Q4
$15.2M Buy
+107,400
New +$15.2M 0.01% 1058

Other funds holding CNMD

Barclays's CNMD Position: Q2 2026 in Review

Barclays reduced its CONMED (CNMD) stake by 76% in Q2 2026, selling an estimated $893K and leaving 7,912 shares worth $259K. The position accounts for ﹤0.01% of the portfolio, ranked #3566.

Barclays first reported a position in CNMD in Q2 2013 and has held it in 51 quarters since. The position peaked at $49.6M in Q2 2023. 246 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

  • Barclays held 7,912 shares of CONMED worth $259K as of Q2 2026.
  • Barclays sold 24,818 CONMED shares in Q2 2026, an estimated $893K.
  • CONMED made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3566 holding.
  • Barclays first reported a position in CONMED in Q2 2013 and has held it in 51 quarters since.
  • Barclays's CONMED position peaked at $49.6M in Q2 2023.
  • 246 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.